Nayak A, Sahoo G, Nishank SS. Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis. World J Gastrointest Oncol 2026; 18(2): 115401 [DOI: 10.4251/wjgo.v18.i2.115401]
Corresponding Author of This Article
Abinash Nayak, MD, Academic Fellow, Assistant Professor, Lecturer, Researcher, Department of Zoology, Utkal University, Vani Vihar, Bhubaneshwar 751004, Odisha, India. abinashnayakzoology@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 15, 2026 (publication date) through Feb 3, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Nayak A, Sahoo G, Nishank SS. Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis. World J Gastrointest Oncol 2026; 18(2): 115401 [DOI: 10.4251/wjgo.v18.i2.115401]
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115401 Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115401
Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis
Abinash Nayak, Gunanidhi Sahoo, Sudhansu Sekhar Nishank, Department of Zoology, Utkal University, Bhubaneshwar 751004, Odisha, India
Author contributions: Nayak A performed literature review, collection and drafting of the manuscript; Sahoo G and Nishank SS performed revision of the manuscript. All authors approved the final version to publish.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abinash Nayak, MD, Academic Fellow, Assistant Professor, Lecturer, Researcher, Department of Zoology, Utkal University, Vani Vihar, Bhubaneshwar 751004, Odisha, India. abinashnayakzoology@gmail.com
Received: October 17, 2025 Revised: October 24, 2025 Accepted: November 27, 2025 Published online: February 15, 2026 Processing time: 110 Days and 12.5 Hours
Abstract
Gastric cancer poses a significant global health burden, particularly in advanced human epidermal growth factor receptor 2-negative cases where prognosis remains poor despite advances in immunochemotherapy. The recent study by Yao et al introduces a nomogram model integrating programmed death ligand 1 expression, microsatellite status, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index to predict progression-free and overall survival. This letter discusses the model’s strengths, limitations, and its alignment with recent developments in biomarkers and therapies, emphasizing its potential for personalized medicine.
Core Tip: The nomogram by Yao et al represents a comprehensive tool for prognosticating outcomes in advanced human epidermal growth factor receptor 2-negative gastric cancer patients on immunochemotherapy. By incorporating immune, clinicopathological, and inflammatory markers, it achieves high discriminative power. Recent advancements in circulatory tumor DNA, artificial intelligence-radiomics, and combination therapies like claudin 18.2-targeting complement this model, highlighting the need for prospective validation to enhance clinical utility.
